Development and Characterization of Novel Selective, Non-Basic Dopamine D₂ Receptor Antagonists for the Treatment of Schizophrenia.

ABSTRACT: The dopamine D₂ receptor, which belongs to the family of G protein-coupled receptors (GPCR), is an important and well-validated drug target in the field of medicinal chemistry due to its wide distribution, particularly in the central nervous system, and involvement in the pathomechanism of many disorders thereof. Schizophrenia is one of the most frequent diseases associated with disorders in dopaminergic neurotransmission, and in which the D₂ receptor is the main target for the drugs used. In this work, we aimed at discovering new selective D₂ receptor antagonists with potential antipsychotic activity. Twenty-three compounds were synthesized, based on the scaffold represented by the D2AAK2 compound, which was discovered by our group. This compound is an int

SUBMITTER: Stepnicki P 

PROVIDER: S-EPMC10223470 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature